Drug Dealin

• Ep. 5: How to Talk to Doctors | Feat. Joe McCann, Co-Founder/CEO of Slingshot Insights

  Summary:In this episode we chat with Joe McCann, CEO of Slingshot Insights. Joe estimates he has done somewhere between 5-10K calls interviewing physicians. In today's episode we tap into his insights on how to get more out of your conversations with doctors. Joe opens up his expert playbook on how to prepare and conduct calls with doctors. We also discuss how these tips/tricks can be applied by the everyday person to get more out of your interactions with healthcare practitioners and ensure you are getting the best care possible. Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.PROMO CODE:DD Pod listeners who sign up for a "Starter" membership at Sling Shot Insights can get their first month FREE by entering the promo code: drugdealinpod25 at checkoutLearn more about slingshot at: www.slingshotinsights.comContact Joe McCann:Email: [email protected]: @JMac_SIContact us:Questions?: ⁠[email protected]⁠Follow us on X: ⁠⁠https://x.com/DrugDealinPod⁠⁠Follow Shivu : ⁠⁠https://linktr.ee/shivusharma⁠⁠Subscribe to Shivu's newsletter: ⁠https://www.bigpharmasharma.com/⁠Follow Kenny: ⁠⁠https://www.linkedin.com/in/kennylalwani/⁠Chapters00:00 Recap of Insights from Joe's Conversation03:05 Introduction to Expert Calls and Their Importance11:10 Joe McCann's Background and Journey18:52 Understanding the Value of Expert Calls26:46 Differentiating Between Academic and Community Physicians32:33 Risk Profiles and Decision-Making in Medicine32:49 Managing Patient Care and Treatment Options34:45 Navigating Expert Calls and Communication Strategies37:22 Understanding Bias in Medical Opinions41:34 Identifying Red Flags in Expert Interactions45:30 Differentiating Client Needs: Investors vs. Industry47:41 The Importance of Follow-Up Calls50:42 Patient Engagement and Empowerment57:09 Utilizing Guidelines and Resources for Better Care01:00:44 The Importance of Proactive Healthcare01:05:15 Navigating Clinical Trials and Patient Advocacy01:08:48 Understanding Quality of Life in Treatment Decisions01:09:55 Surgery Insights: Complications and Surgeon Selection01:19:01 Entrepreneurship in Healthcare: Joe's Journey01:25:20 Recap of Insights from Joe's Conversation01:27:58 Building Confidence in Patient-Doctor Interactions01:30:41 The Importance of Communication and Understanding01:33:35 Navigating the Healthcare System Effectively01:35:59 The Role of KOLs vs Community Physicians01:38:37 The Impact of AI in Healthcare01:41:18 Outro

  --------  

  1:41:29

  --------

  1:41:29
• Ep.4: Ozempic for the Brain, A New Era to Explain

  Summary: In this episode, Shivu and Kenny delve into the evolving landscape of GLP-1 drugs, particularly focusing on the recent advancements in oral formulations and their potential applications beyond diabetes and obesity, including CNS diseases and addiction. They discuss the challenges of adherence, the mechanisms of action, and the economic implications of these therapies, while also highlighting the importance of early intervention in treatment. The conversation emphasizes the promising future of GLP-1s in various therapeutic areas and the ongoing research that will shape their role in healthcare.References:Shivu's recent substack post discussing GLP-1s for CNS disease: https://www.bigpharmasharma.com/p/what-2025-holds-for-glp-1s-in-brainGLP-1 Growth Graph: Zheng, Z., Zong, Y., Ma, Y. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024).Contact us:Questions?: [email protected] us on X: ⁠https://x.com/DrugDealinPod⁠Follow Shivu : ⁠https://linktr.ee/shivusharma⁠Subscribe to Shivu's newsletter: https://www.bigpharmasharma.com/Follow Kenny: ⁠https://www.linkedin.com/in/kennylalwani/⁠Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.Chapters00:00 Introduction to GLP-1s02:52 The Evolution of Oral GLP-1s06:26 Challenges in Patient Adherence10:34 Exploring CNS Impacts of GLP-1s14:44 Mechanisms of Action in CNS Diseases19:13 Potential in Addiction Treatment24:23 Future Directions and Research Opportunities30:20 Exploring the Mechanisms of New Medications35:16 Long-term Use and Dosing Challenges39:57 Promising Data in Addiction Treatment43:56 The Future of CNS and Metabolic Dysfunction Treatments50:44 The Path Forward in Drug Development54:50 Outro

  --------  

  54:59

  --------

  54:59
• Ep 3: Rise of the Phoenix | Sujal Shah & CymaBay Therapeutics

  A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity. Questions?: [email protected] Follow us on X: https://x.com/DrugDealinPodConnect with Shivu: https://linktr.ee/shivusharmaCheck out Big Pharma Sharma: https://bigpharmasharma.substack.com/ Connect with Kenny: https://www.linkedin.com/in/kennylalwani/ Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.00:00 Introduction to Biotech Leadership 03:00 Sujal Shah's Journey in Biotech05:46 Leadership Philosophy and Team Dynamics 09:13 Navigating Challenges at CymaBay 11:48 The Development of seladelpar 15:07 Strategic Decisions in Drug Development 17:58 Clinical Trials and Regulatory Interactions 20:50 The NASH Study and Its Implications 47:10 Navigating Drug Development Challenges 49:07 The Patient-Centric Approach in Drug Development 51:56 Facing Clinical Setbacks and Organizational Resilience 53:36 Unexpected Findings and Immediate Reactions 01:00:27 The Emotional Toll of Drug Development 01:05:08 Rebuilding Purpose and Finding Answers 01:19:52 Patient Advocacy and Support During Crisis 01:23:30 Uncovering the Truth: The Role of Independent Panels 01:33:59 Independent Review and Safety Assurance 01:36:50 Leadership Challenges and Stakeholder Management 01:40:12 Resilience in Adversity 01:43:51 Turning Point: Stock Recovery and Investor Relations 01:47:07 Skepticism and Ongoing Challenges 01:55:00 Data Presentation and Competitive Landscape 02:01:11 Building a Robust Evidence Package 02:04:53 Reflections on Leadership and Future Aspirations

  --------  

  2:20:49

  --------

  2:20:49
• Ep. 2: Predictions for Biopharma in 2025

  Kenny and Shivu each cook up three predictions for Biopharma in 2025NOTE: This episode was recorded on January 10th, 2025Have feedback for us? Leave a comment or email us at [email protected]: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.

  --------  

  57:57

  --------

  57:57
• Ep. 1: Do Pharma Companies Avoid Cures?

  In this episode, we unpack, examine, and debunk the public perception that drug companies intentionally do not pursue curative therapies, because it is financially less beneficial to them. We speak from our own experience working on curative therapies in Oncology and HCV, discuss how difficult it is to develop cures, the implications of curing a disease for drug companies, and how the industry can do a better job fostering trust with patients.Have feedback for us? Feel free to leave a comment or send us an email at [email protected]: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.

  --------  

  1:13:48

  --------

  1:13:48

More Science podcasts

Trending Science podcasts

About Drug Dealin